Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT

Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT

TP53 gene alteration confers inferior prognosis in refractory/relapse aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL). From September 2016 to September 2020, 257 r/r B-NHL patients were assessed for eligibility for two trials in our center, assessing anti-CD19 and anti-CD22 chimeric antigen recep...

Full description

Bibliographic Details
Main Authors: Cao, Y. (Author), Chen, L. (Author), Huang, L. (Author), Mao, Z. (Author), Meng, F. (Author), Sun, W. (Author), Wang, N. (Author), Wang, Y. (Author), Wei, J. (Author), Xiao, M. (Author), Xiao, Y. (Author), Yang, X. (Author), Zhang, S. (Author), Zhang, T. (Author), Zhang, Y. (Author), Zhou, J. (Author), Zhu, H. (Author)
Format: Article
Language:English
Published: Springer Nature 2022
Subjects:
autotransplantation
B cell lymphoma
genetics
hematopoietic stem cell transplantation
Hematopoietic Stem Cell Transplantation
human
Humans
Lymphoma, B-Cell
protein p53
Receptors, Chimeric Antigen
T lymphocyte
T-Lymphocytes
TP53 protein, human
Transplantation, Autologous
Tumor Suppressor Protein p53
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items